Clearside Biomedical to Report Third Quarter 2019 Financial Results and Provide Corporate Update on Wednesday, November 6, 20...
30 Octubre 2019 - 2:05PM
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical
company dedicated to developing and delivering treatments that
restore and preserve vision for people with serious back of the eye
diseases, announced today that its third quarter 2019 financial
results will be reported on Wednesday, November 6, 2019 after the
close of the financial markets. Management will host a webcast and
conference call at 4:30 p.m. Eastern Time to discuss the results
and provide a corporate update.
The live and archived webcast may be accessed on
the Clearside website under the Investors section: Events and
Presentations. The live call can be accessed by dialing (844)
263-8310 (domestic) or (213) 358-0959 (international) and entering
conference code: 1137365. An archive of the webcast will be
available for three months.
About Clearside Biomedical
Clearside Biomedical, Inc. is a
biopharmaceutical company dedicated to developing and delivering
treatments that restore and preserve vision for people with serious
back of the eye diseases. Clearside’s proprietary SCS
Microinjector™ targeting the suprachoroidal space (SCS) offers
unique access to the macula, retina and choroid where
sight-threatening disease often occurs. The Company’s SCS injection
platform is an inherently flexible, in-office, non-surgical
procedure, intended to provide targeted delivery to the site of
disease and to work with both established and new formulations of
medications, as well as future therapeutic innovations such as gene
therapy. For more information, please visit
www.clearsidebio.com.
Investor and Media Contacts: Jenny Kobin Remy
Bernarda ir@clearsidebio.com(678) 430-8206
Source: Clearside Biomedical, Inc.
Clearside Biomedical (NASDAQ:CLSD)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Clearside Biomedical (NASDAQ:CLSD)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024